Core Scientific, Inc/tx

Core Scientific has appointed Mark W. Adams, a seasoned technology executive with extensive experience in AI infrastructure and semiconductors, to its Board of Directors.

Core Scientific announced robust second quarter 2026 financial results, highlighted by significant growth in colocation revenue and a strategic partnership with AMD.

Core Scientific and AMD announce a strategic partnership to provide up to 2.5 gigawatts of AI-ready data center capacity, with initial deployments starting in 2027.

Core Scientific has appointed Steve Smith, a seasoned executive with extensive experience in the data center and digital infrastructure sectors, to its Board of Directors and Nominating and Corporate Governance Committee.

Core Scientific stockholders re-elected five directors and ratified the appointment of KPMG LLP as the company's auditor.

Core Scientific announced its first quarter 2026 financial results, highlighting significant revenue growth driven by colocation services and a substantial expansion of its power capacity pipeline.

Core Scientific Inc. reported a significant increase in total revenue to $164.2 million for the three months ended June 30, 2026, driven by its strategic transition to high-density colocation services.

Core Scientific reports Q1 2026 revenue of $115.2 million, driven by high-density colocation growth despite a net loss of $347.2 million.

Core Scientific, Inc. has filed an amended quarterly report for Q3 2025, restating prior financial statements due to errors in property, plant, and equipment accounting and disclosing a material weakness in internal controls, while also progressing with its CoreWeave merger.

Core Scientific filed an amended quarterly report for Q2 2025, restating prior financials due to errors in asset capitalization and disclosing a material weakness in internal controls, while also announcing a merger with CoreWeave.

Core Scientific, Inc. has filed an amended quarterly report for Q1 2025, restating financial statements due to errors in property capitalization and disclosing a material weakness in internal controls.

Core Scientific reports a significant net loss in Q3 2025, driven by a strategic pivot from digital asset mining to high-density colocation services, alongside a pending all-stock merger with CoreWeave.

Core Scientific, Inc. reports a net loss of $288.6 million for 2025, driven by a strategic pivot from digital asset self-mining to high-density colocation services for AI and HPC workloads, despite increased colocation revenue.

Core Scientific emerges from bankruptcy in 2024, reporting a strategic shift towards HPC hosting while maintaining its digital asset mining operations.

Core Scientific emerges from Chapter 11 bankruptcy, reports a net loss of $246.5 million for 2023, and announces a new data center contract with CoreWeave.

Mark Adams, a Director of Core Scientific, Inc./tx, received 27,594 shares of common stock on July 30, 2026.

Todd M Duchene, See remarks of Core Scientific, Inc./tx, sold 10,000 shares of common stock on July 27, 2026.

Todd M Duchene, See remarks of Core Scientific, Inc./tx, sold 10,000 shares of common stock on July 20, 2026 for $22.30 per share.

Adam Taylor Sullivan, Chief Executive Officer and a Director of Core Scientific, Inc./tx, reported a transaction in 15,584 shares of common stock on July 16, 2026.

Todd M Duchene, See remarks of Core Scientific, Inc./tx, reported a transaction in 4,325 shares of common stock on July 16, 2026.

Todd M Duchene, See remarks of Core Scientific, Inc./tx, sold 10,000 shares of common stock on July 13, 2026.

Core Scientific reports significant progress in 2025, expanding its high-density colocation infrastructure for AI and HPC, with over $10 billion in projected revenue from a 12-year CoreWeave agreement.

Two Seas Capital LP, a major shareholder, is actively soliciting votes AGAINST Core Scientific's proposed acquisition by CoreWeave, citing a flawed process, deficient structure, and inadequate valuation.

Core Scientific's board unanimously recommends an all-stock merger with AI hyperscaler CoreWeave, offering stockholders a 27.2% premium and a stake in a rapidly growing AI infrastructure leader.

Core Scientific's 2025 proxy statement outlines strategic priorities including infrastructure expansion, customer diversification, and potential acquisitions, reflecting its transformation into a leading provider of high-performance computing and AI-driven data center solutions.

Core Scientific files an amendment to its S-1 registration statement for the resale of approximately 10.8 million shares of common stock by selling stockholders following its emergence from Chapter 11 bankruptcy.

Core Scientific registers for the resale of up to 10.7 million shares of its common stock by selling stockholders following its emergence from Chapter 11 bankruptcy.

Reporting persons associated with Core Scientific, Inc. have disclosed substantial sales of the company's common stock over the past 60 days, reducing their beneficial ownership.

Two Seas Capital LP has disclosed a reduction in its beneficial ownership of Core Scientific, Inc. to below the 5% threshold.

Two Seas Capital LP has reported a 5.7% beneficial ownership stake in Core Scientific, Inc. through a Schedule 13D filing.

Two Seas Capital LP has agreed to waive a deadline for Core Scientific, Inc. to appoint an independent director, extending it to May 30, 2026.

Two Seas Capital LP and its affiliates updated their beneficial ownership in Core Scientific, Inc. to 5.9%, detailing recent stock and options transactions.

Core Scientific, Inc. and Two Seas Capital LP have entered a cooperation agreement, leading to significant board changes and a standstill on Two Seas Capital's share accumulation.

Vanguard Capital Management has reported beneficial ownership of 16,196,304 shares, representing 5.09% of the outstanding common stock of Core Scientific Inc.

Jane Street Group, LLC, along with its affiliates, has reported beneficial ownership of 7.5% of Core Scientific, Inc.'s common stock, totaling 23,967,780 shares.

Valiant Capital Management, L.P. and Christopher R. Hansen have reported a 5.1% beneficial ownership stake in Core Scientific, Inc. common stock.

Citadel Securities and affiliated entities have reported a 4.1% beneficial ownership stake in Core Scientific, Inc. common stock.

Multiple entities within the Susquehanna Investment Group have collectively reported beneficial ownership of 4.6% of Core Scientific, Inc. common stock as of March 31, 2025.

Vanguard Portfolio Management has reported beneficial ownership of 18,843,184 shares, representing 5.97% of Core Scientific Inc.'s common stock, as of March 31, 2026.